Research-based alliances between Chinese and Western pharma/biotech partners have been on an upward arc over the past year, driven by the desire of smaller US and European companies to gain access to China's growing market and their Chinese counterparts' rising hunger for innovation.
Research-based alliances between Chinese and Western pharma/biotech partners have been on an upward arc over the past year, driven by the desire of smaller US and European companies to gain access to China's growing market and their Chinese counterparts' rising hunger for innovation.
A new deal between Ambrx and Zhejiang Medicine Company (ZMC) has some additional mutual benefits as well. For one, it...
Create an account to read this article
Already a subscriber?
The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.
